Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.41 |
| ▸ | NPY1R | P25929 | 8/20 | 0.41 |
| ▸ | NPY2R | P49146 | 6/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 2/20 | 0.38 |
| ▸ | FNTB | P49356 | 2/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533613 | 0.93 | NPY4R (0.47) | NPY4RNPY5RNPY1RNPY2RACE | |
| SCHEMBL29533805 | 0.93 | QRFPR (0.43) | NPY4RNPY5RNPY1RNPY2RACE | |
| SCHEMBL3952924 | 0.92 | SLC15A2 (0.44) | NPY4RNPY5RNPY1RNPY2RSLC15A2 | |
| SCHEMBL3952951 | 0.92 | SLC15A2 (0.44) | NPY4RNPY5RNPY1RNPY2RSLC15A2 | |
| SCHEMBL29875467 | 0.92 | SLC15A2 (0.44) | NPY4RNPY5RNPY1RNPY2RSLC15A2 | |
| SCHEMBL29875780 | 0.92 | SLC15A2 (0.44) | NPY4RNPY5RNPY1RNPY2RSLC15A2 | |
| SCHEMBL29534002 | 0.92 | NPY4R (0.44) | NPY4RNPY5RNPY1RNPY2RACE | |
| SCHEMBL28933203 | 0.92 | PTGS1 (0.42) | NPY4RNPY5RNPY1RNPY2RACE | |
| SCHEMBL28933196 | 0.92 | PTGS1 (0.42) | NPY4RNPY5RNPY1RNPY2RACE | |
| SCHEMBL31557707 | 0.90 | SLC15A2 (0.42) | NPY4RNPY5RNPY1RNPY2RSLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20220133904-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER | PAUL SCHERRER INSTITUT (CH) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133904-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER | TGM3, TGM2, GLUL | NPY4R 2474/4885NPY5R 2019/4885NPY1R 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.